Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis
Published in: | ESMO Open |
---|---|
Main Authors: | , , , , , , |
Format: | Text |
Language: | English |
Published: |
BMJ Publishing Group
2017
|
Subjects: | |
Online Access: | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703383/ http://www.ncbi.nlm.nih.gov/pubmed/29209527 https://doi.org/10.1136/esmoopen-2017-000222 |
id |
ftpubmed:oai:pubmedcentral.nih.gov:5703383 |
---|---|
record_format |
openpolar |
spelling |
ftpubmed:oai:pubmedcentral.nih.gov:5703383 2023-05-15T17:43:14+02:00 Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis Norum, Jan Antonsen, Margareth Aarag Tollåli, Terje Al-Shibli, Khalid Andersen, Gry Svanqvist, Kristin Helene Helbekkmo, Nina 2017-07-29 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703383/ http://www.ncbi.nlm.nih.gov/pubmed/29209527 https://doi.org/10.1136/esmoopen-2017-000222 en eng BMJ Publishing Group http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703383/ http://www.ncbi.nlm.nih.gov/pubmed/29209527 http://dx.doi.org/10.1136/esmoopen-2017-000222 © European Society for Medical Oncology (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ CC-BY-NC Original Research Text 2017 ftpubmed https://doi.org/10.1136/esmoopen-2017-000222 2017-12-10T01:12:51Z Text Northern Norway PubMed Central (PMC) Norway ESMO Open 2 3 e000222 |
institution |
Open Polar |
collection |
PubMed Central (PMC) |
op_collection_id |
ftpubmed |
language |
English |
topic |
Original Research |
spellingShingle |
Original Research Norum, Jan Antonsen, Margareth Aarag Tollåli, Terje Al-Shibli, Khalid Andersen, Gry Svanqvist, Kristin Helene Helbekkmo, Nina Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis |
topic_facet |
Original Research |
format |
Text |
author |
Norum, Jan Antonsen, Margareth Aarag Tollåli, Terje Al-Shibli, Khalid Andersen, Gry Svanqvist, Kristin Helene Helbekkmo, Nina |
author_facet |
Norum, Jan Antonsen, Margareth Aarag Tollåli, Terje Al-Shibli, Khalid Andersen, Gry Svanqvist, Kristin Helene Helbekkmo, Nina |
author_sort |
Norum, Jan |
title |
Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis |
title_short |
Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis |
title_full |
Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis |
title_fullStr |
Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis |
title_full_unstemmed |
Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis |
title_sort |
pembrolizumab as second-line therapy in non-small cell lung cancer in northern norway: budget impact and expected gain—a model-based analysis |
publisher |
BMJ Publishing Group |
publishDate |
2017 |
url |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703383/ http://www.ncbi.nlm.nih.gov/pubmed/29209527 https://doi.org/10.1136/esmoopen-2017-000222 |
geographic |
Norway |
geographic_facet |
Norway |
genre |
Northern Norway |
genre_facet |
Northern Norway |
op_relation |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703383/ http://www.ncbi.nlm.nih.gov/pubmed/29209527 http://dx.doi.org/10.1136/esmoopen-2017-000222 |
op_rights |
© European Society for Medical Oncology (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
op_rightsnorm |
CC-BY-NC |
op_doi |
https://doi.org/10.1136/esmoopen-2017-000222 |
container_title |
ESMO Open |
container_volume |
2 |
container_issue |
3 |
container_start_page |
e000222 |
_version_ |
1766145260937805824 |